Clinical trials
Cognitive Dysfunction trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
72 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 4 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 9 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 9 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 13 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Unknown status | 20 |
| Recruiting | 12 |
| Active, not recruiting | 7 |
| Terminated | 2 |
| Suspended | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Samsung Medical Center | 7 |
| Inha University Hospital | 6 |
| Seoul National University Hospital | 6 |
| Pusan National University Yangsan Hospital | 5 |
| Seoul National University Bundang Hospital | 3 |
| Chungnam National University | 2 |
| Eli Lilly and Company | 2 |
| Hoffmann-La Roche | 2 |
| Jae Seung Kim | 2 |
| Sahmyook University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cognitive Dysfunction | 72 |
| Alzheimer Disease | 28 |
| Dementia | 14 |
| Neurodegenerative Diseases | 4 |
| Brain Diseases | 3 |
| Lymphoma, Follicular | 3 |
| Stroke | 3 |
| Cognition Disorders | 2 |
| Dementia, Vascular | 2 |
| Disease | 2 |
Trials
Showing 1 to 25 of 72. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.